A novel haplo-identical adoptive CTL therapy as a treatment for EBV-associated lymphoma after stem cell transplantation

Cancer Immunology, Immunotherapy

Volumn 59, Issue 3, 2010, Pages 473-477

  Uhlin, Michael ^a   Okas, Mantas ^a   Gertow, Jens ^a   Uzunel, Mehmet ^a   Brismar, Torkel B ^a   Mattsson, Jonas ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Adoptive transfer; EBV lymphoma; Pentamer; T cells

Indexed keywords

CYCLOSPORIN; EPSTEIN BARR VIRUS SPECIFIC T LYMPHOCYTE; IMMUNOMODULATING AGENT; PREDNISOLONE; RAPAMYCIN; RITUXIMAB; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RISK; CASE REPORT; CELL ACTIVITY; CELL SPECIFICITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; ISOLATION PROCEDURE; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MOTHER; MULTIPLE CYCLE TREATMENT; ORGAN DONOR; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PROPHYLAXIS; TISSUE INJURY; VIRUS INFECTION;

ADOLESCENT; ADOPTIVE TRANSFER; CORD BLOOD STEM CELL TRANSPLANTATION; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOMA; T-LYMPHOCYTES, CYTOTOXIC;

EID: 73349108055     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-009-0789-1     Document Type: Article

References (16)

1. HA Hou M Yao JL Tang YK Chen BS Ko SY Huang HF Tien HH Chang MY Lu TT Lin KH Lin CH Hsiao CW Lin YC Chen 2009 Poor outcome in post transplant lymphoproliferative disorder with pulmonary involvement after allogeneic hematopoietic SCT: 13 years' experience in a single institute Bone Marrow Transplant 43 4 315 321 10.1038/bmt.2008.325 18836488
2. M Sundin K Le Blanc O Ringden L Barkholt B Omazic C Lergin V Levitsky M Remberger 2006 The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation Haematologica 91 8 1059 1067 16885046
3. RJ Murray MG Kurilla JM Brooks WA Thomas M Rowe E Kieff AB Rickinson 1992 Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies J Exp Med 176 1 157 168 10.1084/jem.176.1.157 1:CAS:528: DyaK38Xks1yit78%3D 1319456
4. VP Khatri RA Baiocchi R Peng AR Oberkircher JM Dolce PM Ward GP Herzig MA Caligiuri 1999 Endogenous CD8+ T cell expansion during regression of monoclonal EBV-associated posttransplant lymphoproliferative disorder J Immunol 163 1 500 506 1:CAS:528:DyaK1MXktF2rsbg%3D 10384154
5. CG Brunstein DJ Weisdorf T DeFor JN Barker J Tolar JA van Burik JE Wagner 2006 Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation Blood 108 8 2874 2880 10.1182/blood-2006-03-011791 1:CAS:528:DC%2BD28XhtFWgtLrM 16804113 (Pubitemid 44777029)
6. JE Davis DJ Moss 2004 Treatment options for post-transplant lymphoproliferative disorder and other Epstein-Barr virus-associated malignancies Tissue Antigens 63 4 285 292 10.1111/j.0001-2815.2004.00227.x 1:STN:280:DC%2BD2c7itVOgtg%3D%3D 15009802 (Pubitemid 38406691)
7. A Gustafsson V Levitsky JZ Zou T Frisan T Dalianis P Ljungman O Ringden J Winiarski I Ernberg MG Masucci 2000 Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells Blood 95 3 807 814 1:CAS:528:DC%2BD3cXotV2itg%3D%3D 10648390
8. CM Rooney CA Smith CY Ng SK Loftin JW Sixbey Y Gan DK Srivastava LC Bowman RA Krance MK Brenner HE Heslop 1998 Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients Blood 92 5 1549 1555 1:CAS:528:DyaK1cXls1Siu7w%3D 9716582
9. M Cobbold N Khan B Pourgheysari S Tauro D McDonald H Osman M Assenmacher L Billingham C Steward C Crawley E Olavarria J Goldman R Chakraverty P Mahendra C Craddock PA Moss 2005 Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers J Exp Med 202 3 379 386 10.1084/jem.20040613 1:CAS:528:DC%2BD2MXntFCjt7k%3D 16061727 (Pubitemid 41126955)
10. JP Hancock NJ Goulden A Oakhill CG Steward 2003 Quantitative analysis of chimerism after allogeneic bone marrow transplantation using immunomagnetic selection and fluorescent microsatellite PCR Leukemia 17 1 247 251 10.1038/sj.leu.2402759 1:CAS:528:DC%2BD3sXjsFyltw%3D%3D 12529688 (Pubitemid 36175916)
11. GK Hong ML Gulley WH Feng HJ Delecluse E Holley-Guthrie SC Kenney 2005 Epstein-Barr virus lytic infection contributes to lymphoproliferative disease in a SCID mouse model J Virol 79 22 13993 14003 10.1128/JVI.79.22.13993-14003.2005 1:CAS:528:DC%2BD2MXht1ShsLrP 16254335 (Pubitemid 41552698)
12. D Adhikary U Behrends A Moosmann K Witter GW Bornkamm J Mautner 2006 Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins J Exp Med 203 4 995 1006 10.1084/jem.20051287 1:CAS:528:DC%2BD28Xjsl2isL8%3D 16549597
13. D Adhikary U Behrends H Boerschmann A Pfunder S Burdach A Moosmann K Witter GW Bornkamm J Mautner 2007 Immunodominance of lytic cycle antigens in epstein-barr virus-specific CD4+ T cell preparations for therapy PLoS One 2 7 e583 10.1371/journal.pone.0000583 17611619 (Pubitemid 351266394)
14. GK Hong P Kumar L Wang B Damania ML Gulley HJ Delecluse PJ Polverini SC Kenney 2005 Epstein-Barr virus lytic infection is required for efficient production of the angiogenesis factor vascular endothelial growth factor in lymphoblastoid cell lines J Virol 79 22 13984 13992 10.1128/JVI.79.22.13984- 13992.2005 1:CAS:528:DC%2BD2MXht1ShsLrO 16254334 (Pubitemid 41552697)
15. A De Geer R Kiessling V Levitsky J Levitskaya 2006 Cytotoxic T lymphocytes induce caspase-dependent and -independent cell death in neuroblastomas in a MHC-nonrestricted fashion J Immunol 177 11 7540 7550 17114423
16. T Haque GM Wilkie MM Jones CD Higgins G Urquhart P Wingate D Burns K McAulay M Turner C Bellamy PL Amlot D Kelly A MacGilchrist MK Gandhi AJ Swerdlow DH Crawford 2007 Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial Blood 110 4 1123 1131 10.1182/blood-2006-12-063008 1:CAS:528:DC%2BD2sXptFKmu78%3D 17468341 (Pubitemid 47281407)